# A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Source: https://onco.cc/trials/nct06624644/  
OnCo record `nct06624644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing LNS8801 in melanoma, now recruiting.

## Summary

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma is a phase 2/3 interventional study registered as NCT06624644, led by Linnaeus Therapeutics, and recruiting on the registry. Official title: A Multicenter, Open-Label, Randomised, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma. Planned enrolment is 135 participants (estimated). The study started in 2025-08-06 and primary completion is expected in 2029-02. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06624644
- Phase: 2/3
- Setting: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
- Sponsor: Linnaeus Therapeutics
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT06624644: https://clinicaltrials.gov/study/NCT06624644

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [LNS8801](https://onco.cc/drugs/lns8801/)
- companies: [Linnaeus Therapeutics](https://onco.cc/companies/linnaeus-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06624644.json